Stefani A, Spadoni F, Bernardi G
IRCCS Ospedale S. Lucia, Rome, Italy.
Exp Neurol. 1997 Sep;147(1):115-22. doi: 10.1006/exnr.1997.6554.
Among the several classes of drugs currently studied as neuroprotective agents, glutamate release blockers have been indicated as being rather effective. In particular, lamotrigine and riluzole have shown promise in the treatment of either acutely developing cellular damages (stroke, posttraumatic lesions) or slowly progressing neurodegenerative diseases as amyotrophic lateral sclerosis. These drugs are supposed to interfere with the release of endogenous glutamate in situ, yet the mechanisms underlying this effect are not fully defined. One possibility is that lamotrigine and riluzole act by inhibiting voltage-dependent inward conductances active in the soma and/or in the axon terminal region. Therefore, we have investigated the effects of lamotrigine and riluzole on the voltage-gated sodium and calcium currents of acutely isolated neurons from the adult rat neocortex. In addition, since phenytoin is a well-known blocker of the sodium channel, we have compared lamotrigine and riluzole responses with the peak current inhibition produced by phenytoin in the same cells. Lamotrigine produced a large reduction of the high-voltage-activated calcium currents and a smaller; use-dependent inhibition of the sodium conductance. Riluzole inhibited significantly the sodium current at surprisingly low concentrations (nanomolar range) and by up to 80% at saturating doses (1-10 microM). Furthermore, riluzole inhibited both high- and low-voltage-activated calcium currents in neocortical neurons isolated from adult and young animals. By contrast, phenytoin caused only a slight reduction of high-voltage-activated calcium currents even at supratherapeutic doses (by < 12% at 10 microM). Taken together, the different pharmacological profiles of the tested agents might indicate that glutamate release blockers do not represent a homogenous class of drugs. Conversely, our findings could support their selective utilization in different disease status.
在目前作为神经保护剂进行研究的几类药物中,谷氨酸释放阻滞剂已被证明相当有效。特别是,拉莫三嗪和利鲁唑在治疗急性发生的细胞损伤(中风、创伤后病变)或缓慢进展的神经退行性疾病如肌萎缩侧索硬化症方面已显示出前景。这些药物被认为在原位干扰内源性谷氨酸的释放,但其作用的潜在机制尚未完全明确。一种可能性是拉莫三嗪和利鲁唑通过抑制在胞体和/或轴突终末区域活跃的电压依赖性内向电流起作用。因此,我们研究了拉莫三嗪和利鲁唑对成年大鼠新皮质急性分离神经元的电压门控钠电流和钙电流的影响。此外,由于苯妥英是一种众所周知的钠通道阻滞剂,我们将拉莫三嗪和利鲁唑的反应与苯妥英在相同细胞中产生的峰值电流抑制进行了比较。拉莫三嗪使高电压激活的钙电流大幅降低,对钠电导的使用依赖性抑制较小。利鲁唑在令人惊讶的低浓度(纳摩尔范围)下就能显著抑制钠电流,在饱和剂量(1 - 10 microM)下抑制率高达80%。此外,利鲁唑抑制成年和幼年动物分离的新皮质神经元中的高电压和低电压激活的钙电流。相比之下,即使在超治疗剂量下(10 microM时降低<12%),苯妥英也仅使高电压激活的钙电流略有降低。综上所述,所测试药物的不同药理学特征可能表明谷氨酸释放阻滞剂并非一类同质的药物。相反,我们的研究结果可能支持它们在不同疾病状态下的选择性应用。